TY - JOUR
T1 - The Use of Protease Inhibitors in Pregnancy
T2 - Maternal and Fetal Considerations
AU - Duryea, Elaine
AU - Nicholson, Fiona
AU - Cooper, Sara
AU - Roberts, Scott
AU - Rogers, Vanessa
AU - McIntire, Donald
AU - Sheffield, Jeanne
AU - Stewart, Robert
N1 - Publisher Copyright:
© 2015 Elaine Duryea et al.
PY - 2015
Y1 - 2015
N2 - Background. Previous studies examining protease inhibitor use in pregnancy and the rate of preterm and small-for-gestational-age infants have yielded conflicting results. Methods. This was a retrospective study of HIV-infected women who delivered singleton infants at our institution between 1984 and 2014. Women with protease inhibitor use were compared to women on regimens without a protease inhibitor as well as those who received no antepartum antiretroviral therapy. Infants were considered preterm if less than 37 completed weeks of gestation and small-for-gestational-age if less than 10th percentile. Results. During the study period 1,004 pregnancies met inclusion criteria. Of those, 597 received a protease inhibitor as part of their regimen, 230 ART without a protease inhibitor, and 177 no ART. There was no difference in the rate of preterm birth between groups who received ART with or without a protease inhibitor, 14% versus 13%. There was no difference in the rate of small-for-gestational-age infants between the three groups. Use of a protease inhibitor was associated with a greater fall in viral load during pregnancy, p<0.001. Conclusion. In this population with access to prenatal care and ART, treatment with protease inhibitors was associated with a greater fall in viral load, but not an increase in small or preterm infants.
AB - Background. Previous studies examining protease inhibitor use in pregnancy and the rate of preterm and small-for-gestational-age infants have yielded conflicting results. Methods. This was a retrospective study of HIV-infected women who delivered singleton infants at our institution between 1984 and 2014. Women with protease inhibitor use were compared to women on regimens without a protease inhibitor as well as those who received no antepartum antiretroviral therapy. Infants were considered preterm if less than 37 completed weeks of gestation and small-for-gestational-age if less than 10th percentile. Results. During the study period 1,004 pregnancies met inclusion criteria. Of those, 597 received a protease inhibitor as part of their regimen, 230 ART without a protease inhibitor, and 177 no ART. There was no difference in the rate of preterm birth between groups who received ART with or without a protease inhibitor, 14% versus 13%. There was no difference in the rate of small-for-gestational-age infants between the three groups. Use of a protease inhibitor was associated with a greater fall in viral load during pregnancy, p<0.001. Conclusion. In this population with access to prenatal care and ART, treatment with protease inhibitors was associated with a greater fall in viral load, but not an increase in small or preterm infants.
UR - http://www.scopus.com/inward/record.url?scp=84947474641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947474641&partnerID=8YFLogxK
U2 - 10.1155/2015/563727
DO - 10.1155/2015/563727
M3 - Article
C2 - 26617456
AN - SCOPUS:84947474641
SN - 1064-7449
VL - 2015
JO - Infectious Diseases in Obstetrics and Gynecology
JF - Infectious Diseases in Obstetrics and Gynecology
M1 - 563727
ER -